Lexaria says one oral semaglutide formula matched its reference in rat blood absorption, as it hunts for an alternative to Novo's SNAC. Three patents are filed.
Recap by typeshit. Full story at Investing News Network.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Users most often reported increased appetite, unlike the stomach issues seen in trials. The authors say it proves nothing causal and only flags leads to test.
Lexaria says some DehydraTECH formulas hit its best absorption yet and filed 3 patents. Semaglutide brain levels were too low to measure in this rat study.
Loading…